An adaptogen is a plant or herb traditionally associated with helping the body respond to physical and mental stress. In the past five years the category has gone from niche wellness to UK high-street ubiquity — Superdrug, Holland & Barrett, Boots and most supermarkets now stock ashwagandha, rhodiola, reishi and several others, alongside a rapidly growing cast of superfood powders and gummies marketing adaptogenic formulations. The category is also, simultaneously, the subject of the most active regulatory scrutiny of any wellness supplement vertical in the UK right now. This guide explains what an adaptogen is, what the UK regulator has said about the word, what the evidence actually supports, and who should think twice before buying one.
An adaptogen is a plant or herb traditionally used to help the body respond to stress. The UK regulator treats the word itself as a specific health claim requiring authorised substantiation. Ashwagandha — the category's most-sold ingredient — is under active FSA safety review and has been banned in Denmark since 2023. Rhodiola has stronger safety standing and reasonable evidence for fatigue-related support. Whichever you take, you need standardised extract at a trial-validated dose, and you need to speak to your GP first if you take any prescription medication.
Where the word came from.
The term "adaptogen" was coined in 1947 by Nikolai Lazarev, a Soviet pharmacologist working on compounds that could increase resistance to stress. His successor Israel Brekhman refined the definition: a substance qualified as an adaptogen if it was harmless to the host, had a non-specific normalising effect (i.e., it seemed to help regardless of the direction of the stressor), and had a general calming action on the body's stress response. The Soviet military-industrial complex of the 1960s and 70s funded significant research into adaptogens, testing compounds like eleutherococcus (Siberian ginseng), rhodiola, and schisandra for their potential to enhance soldier and cosmonaut performance under stress.
The word travelled westward slowly. In Ayurvedic and Traditional Chinese Medicine traditions, substances we now call adaptogens had been used for millennia under different names — ashwagandha in Indian Ayurveda, ginseng in Chinese medicine, reishi mushroom in Chinese and Japanese traditions, holy basil across South Asia. The Soviet pharmacology work provided a Western-pharmaceutical vocabulary for what traditional medicine had already categorised. By the 2000s, the concept had been absorbed by the functional medicine and wellness industries in the US and UK; by 2020, "adaptogen" had become a mainstream supplement-marketing term.
What's worth noting about this history: the concept of an adaptogen is pharmacologically coherent at its origin, and the specific compounds the Soviet researchers identified do have meaningful evidence bases. The modern commercial category, however, has stretched the word to cover nearly any botanical marketed for stress, energy, mood, or wellbeing — often with evidence substantially weaker than the original pharmacological research implied.
How the UK regulator sees it.
The Advertising Standards Authority, working under the CAP Code, regulates nutrition and health claims in UK advertising. Supplements fall under Section 15 — a framework that only permits health claims appearing on the GB Nutrition and Health Claims Register with authorisation.
In a series of rulings from 2024 onwards, the ASA made its position on the word "adaptogen" explicit. When a brand markets a product as "adaptogenic" or uses the word "adaptogen," UK consumers understand this to mean the product helps the body respond to stress. That understanding makes the word a specific health claim, which means the brand can only use it if the specific product and ingredients hold authorised claims on the GB Register relating to stress response. Almost no branded adaptogen formulation holds such claims.
The ASA has upheld rulings against multiple adaptogen-marketing brands since 2024, including Nowt Ventures Ltd (Feel Güd), Ejec Ventures LLC (Auri Nutrition), Nutriburst, Well Gummies, and several others. These rulings typically cover three breaches: unauthorised specific health claims (use of the word "adaptogen"), unauthorised general health claims, and in some cases marketing of unauthorised novel food ingredients (turkey tail mushroom being the most common).
The ASA has effectively ruled that the word "adaptogen" is too strong for what the underlying evidence on most branded products supports. UK brands can sell the products; they are increasingly constrained in what they can say about them.
A separate regulatory story is unfolding around specific ingredients — ashwagandha especially. In 2024 the UK Food Standards Agency issued a formal call for evidence on ashwagandha food supplements, the first step in what has become an active risk assessment by the Committee on Toxicity. The FSA's published concerns include documented effects on thyroid hormone levels, reports of hypoglycaemic effects, and potential liver toxicity. The agency is gathering evidence to determine whether a safe level of intake can be established or whether restrictions are warranted.
The ashwagandha situation, specifically.
Ashwagandha warrants its own section because it is both the most commercially important adaptogen in the UK and the one with the most active regulatory uncertainty. The timeline is worth understanding:
What this means for UK buyers: ashwagandha is currently legal. It has a meaningful evidence base for some traditional uses, a reasonable safety record for most healthy adults at standard doses in short-term use, and specific documented risks for defined populations. It is also in regulatory flux, and the situation may change.
Pregnant or breastfeeding women. Ashwagandha has been associated with potential pregnancy complications and should be avoided.
Anyone with thyroid conditions or taking thyroid medication. Ashwagandha has documented effects on thyroid hormone levels and may interfere with medication.
Anyone with autoimmune conditions — ashwagandha may stimulate immune function in ways that could exacerbate autoimmune issues.
Anyone on sedative medications or blood thinners — potential interaction risks.
Anyone preparing for surgery (stop at least two weeks before any scheduled procedure).
If you take any prescription medication, speak to your GP or pharmacist before starting ashwagandha.
What the evidence actually shows.
Different adaptogens have different evidence bases. Here is an honest assessment of the main ingredients you'll encounter on UK supplement labels, graded by strength of human trial evidence for their traditional use claims. Remember that even ingredients with "moderate" or "strong" evidence can only be marketed with the authorised GB Register claims — the evidence strength below is about the underlying research, not about what a UK brand can lawfully advertise.
Ashwagandha (Withania somnifera)
Meta-analyses support effects on stress markers including cortisol in stressed populations. Effect sizes are modest. KSM-66 and Sensoril are the two most-researched standardised extracts. Typical effective dose: 300-600mg daily of standardised extract over 4-8 weeks. See safety warnings above.
Rhodiola rosea
Multiple human trials support effects on fatigue in stressed populations. Active compounds are rosavins and salidroside. Typical effective dose: 200-400mg of 3% rosavin-standardised extract daily. Well-tolerated in most healthy adults. Avoid during pregnancy.
Lion's Mane (Hericium erinaceus)
Human trials suggest effects on cognitive function, particularly in older adults. Mechanism involves nerve growth factor. Buy fruiting body extract, not mycelium grown on grain substrate. Different evidence base than classical stress-response adaptogens.
Reishi (Ganoderma lucidum)
Extensive traditional use but limited rigorous human trial data. Often included in "calm" blends for its traditional associations with sleep and stress. Safety profile generally reasonable at standard doses.
Shilajit
Resinous substance from Himalayan rock. Traditional Ayurvedic tonic. Limited rigorous human trial data. Quality varies enormously between sources — contamination with heavy metals is a real concern with cheaper imports. Only buy tested product.
Eleutherococcus (Siberian ginseng)
The original Soviet-era adaptogen. Much of the foundational research is from Russian-language journals and predates modern clinical trial standards. Modern evidence base is thinner than the historical claims imply.
Turkey tail (Trametes versicolor)
Classified by the UK FSA as an unauthorised novel food. Cannot lawfully be sold in the UK food supplement market. If you see it in a mushroom blend product, the brand is either non-compliant or operating without adequate regulatory awareness.
Holy basil (Tulsi / Ocimum sanctum)
Some traditional use evidence for stress-response support. Regulatory status varies; some specific extracts are classified as unauthorised novel foods. Check FSA guidance before purchasing extract-based products.
How to read an adaptogen label.
Most adaptogen buyers don't scrutinise the supplement facts panel. It is, however, the single most useful skill for this category. The differences between a well-formulated product and a cosmetic one are all on the back of the bottle.
1. Does it name the specific extract?
"Ashwagandha root extract" is less useful than "Ashwagandha root extract (KSM-66)" or "Ashwagandha root extract (Sensoril)." Named branded extracts come with a standardisation guarantee and a body of research supporting their specific formulation. Unnamed extracts are a black box. The same applies to rhodiola — "3% rosavin-standardised" is meaningful; unstandardised rhodiola is not meaningfully comparable to the trial literature.
2. Does it state the withanolide percentage (for ashwagandha) or rosavin percentage (for rhodiola)?
These are the active compound percentages. KSM-66 is standardised to a minimum of 5% withanolides; Sensoril is standardised to 10% withanolides (but also 32% oligosaccharides, which some research suggests causes more sedation). Rhodiola should be standardised to 3% rosavins and 1% salidrosides. If the percentages are missing, the dose figure on the label is not meaningful.
3. Is the dose within research range?
For ashwagandha, effective doses in human trials typically sit between 300-600mg per day of standardised extract. For rhodiola, 200-400mg of standardised extract. If the product delivers less, it's cosmetic dosing. More than this can be marketed but is not necessarily better-supported and may increase side-effect risk.
4. Is the brand UK-accountable?
UK-registered brands operating under GMP certification are preferable. They are subject to UK food law, ASA rules, and consumer protection legislation. Check the brand's footer for a registered UK address. Amazon-only brands with no findable corporate presence carry more risk.
5. What else is in it?
Multi-ingredient "adaptogen blends" are popular but come with a trade-off: the ashwagandha content in a blend is almost always below the single-ingredient research dose. A blend at £30 that has "18 adaptogens" likely contains each one at a fraction of the researched effective amount. You're buying the concept, not the formulation. If you want to test a specific adaptogen, start with a single-ingredient product at a trial-validated dose.
A realistic expectation check
Most ashwagandha and rhodiola research suggests 4-8 weeks of consistent daily use before effects on stress or fatigue markers register. If you take an adaptogen for three days and notice nothing, that is consistent with the underlying research — they don't typically produce immediate effects.
If a brand promises "dramatic results in days" or "immediate stress relief," that marketing is not consistent with the evidence base. Treat it as a flag about the brand's relationship to the research rather than a claim worth taking seriously.
Red flags worth knowing.
- Turkey tail mushroom in a UK-sold product. Classified as an unauthorised novel food. Brands selling it are operating outside UK regulation.
- Proprietary blends with no individual ingredient doses. Almost always indicates cosmetic dosing across the blend.
- "Cures anxiety" or "treats depression" language. These are medicinal claims, banned under CAP rules, and indicate a brand willing to ignore regulation.
- No withanolide or rosavin percentage. Without it, the milligram figure is meaningless.
- Unstandardised extracts at premium prices. You're paying for marketing rather than formulation.
- Ashwagandha marketed for pregnancy use. The opposite of what FSA guidance and the broader safety literature supports.
- Unknown shilajit sourcing. Heavy metal contamination is a real risk in cheap products.
- Influencer-first brands with no corporate history. Not automatically disqualifying but frequently correlates with thin formulations.
A sensible approach, one paragraph.
If you want to explore the adaptogen category, start with a single-ingredient product at a trial-validated dose from a UK-accountable brand. For stress-related concerns, that's ashwagandha — ideally KSM-66 at 500mg daily — and only if none of the safety flags above apply to you. Speak to your GP first, especially if you take any prescription medication. For fatigue-related concerns, rhodiola standardised to 3% rosavins at 200-400mg daily is a cleaner regulatory starting point. Give either adaptogen four to eight weeks of consistent daily use before drawing conclusions. Don't expect dramatic results. Do expect to pay more for transparent, well-standardised products than for cheaper lookalikes — the extract quality genuinely matters in this category. Our adaptogens buying guide covers our specific recommendations.
Frequently asked questions.
Is "adaptogen" a regulated term?
In UK advertising, yes — the ASA treats the word as a specific health claim requiring authorised substantiation on the GB Register. Outside of advertising, the word is not formally regulated, but the products remain subject to UK food law.
Is ashwagandha safe?
For most healthy adults at standard doses, short-term use has a reasonable safety record. For pregnant women, people with thyroid conditions, those on certain medications, and those with autoimmune conditions, ashwagandha is genuinely risky. The FSA's ongoing risk assessment reflects the existence of documented safety concerns. When in doubt, speak to your GP.
What's the difference between KSM-66 and Sensoril?
Both are branded standardised ashwagandha extracts. KSM-66 is a root-only extract standardised to 5%+ withanolides, with the largest body of research. Sensoril is a root-and-leaf extract standardised to 10%+ withanolides (plus other compounds), associated with more sedation. For first-time users, KSM-66 is the more conservative starting point.
Can I take adaptogens long-term?
Traditional usage frameworks often recommend "cycling" adaptogens — for example, 8 weeks on, 2 weeks off. The evidence for whether cycling matters pharmacologically is limited, but the practice is a reasonable precaution given the long-term safety data is thinner than the short-term data for most of these ingredients.
Can children take adaptogens?
No. The evidence base for adaptogens in under-18s is essentially non-existent, and the regulatory guidance consistently advises against it. Don't give adaptogens to children or adolescents.
Can I combine adaptogens?
Many blend products do exactly this. Whether the combinations work better than single ingredients is an open question — the underlying evidence for specific combinations is thinner than for individual compounds. For your first experience with adaptogens, single ingredients at clinical doses give you better information about what works for you personally.
Why is Denmark's ban relevant to the UK?
Denmark's national food authority has some of the more conservative risk-assessment frameworks in Europe. When Denmark bans an ingredient, other European regulators typically reassess their own positions. The UK has left the EU but regulatory frameworks remain closely related, and FSA decisions often reflect European regulatory thinking.
An adaptogen is a plant traditionally used to help the body respond to stress. Soviet-era pharmacology gave the category its name; traditional Ayurvedic and Chinese medicine traditions have used these compounds for millennia. The UK regulator treats the word "adaptogen" as a health claim requiring substantiation. Ashwagandha is under active FSA safety review; rhodiola is on cleaner regulatory ground. Choose single-ingredient products at trial-validated doses from UK-accountable brands, and speak to your GP if you take any prescription medication.
Further reading.
- FSA Ashwagandha Call for Evidence — the UK regulator's current risk assessment process, including the published safety concerns driving the review
- ASA Supplements Guidance — the UK advertising authority's published rules for supplement marketing
- GB Nutrition and Health Claims Register — the official list of authorised health claims
- Examine.com — an independent, non-commercial database of human trial evidence on individual supplement ingredients